Climb Bio reported a third-quarter 2026 net loss of $14.6 million, or $0.18 per share, compared to a $12.9 million loss in the prior-year period. Research and development expenses rose to $11.0 million from $9.1 million, while general and administrative costs remained steady at $5.8 million. The company ended the quarter with $227.6 million in cash, cash equivalents, and marketable securities, projecting a runway into the second half of 2028. Clinically, Climb Bio initiated dosing in the Phase 2 NAVIGATE-2 trial for CLYM116 in IgA nephropathy and presented initial data from the PrisMN Phase 2 study for budoprutug in primary membranous nephropathy showing B-cell depletion and immunologic remission. The company operates as a clinical-stage biotechnology firm developing monoclonal antibody therapeutics for immune-mediated diseases.
